|
|
||||||||
American Journal of Clinical Nutrition, Vol 55, 173S-176S, Copyright © 1992 by The American Society for Clinical Nutrition, Inc
REVIEW ARTICLES |
B Guy-Grand
Service Medecine et Nutrition, Hotel Dieu Paris, France.
d-Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity and has been shown to increase adherence to diet, to enhance its efficacy, and most importantly, to prevent weight regain when continued over 1 y. Few side effects, mostly transient, have been observed. A long-term use of dF in the management of some obese patients could be foreseen. Additionally, evidence that dF improves eating symptoms and dysphoric impairments in obese cravers, premenstrual syndrome, seasonal affective disorder, and smoking withdrawal syndrome has been presented.
This article has been cited by other articles:
![]() |
X. Lin, D. A. Levitsky, J. M. King, and T. C. Campbell The promotion effect of anorectic drugs on aflatoxin B1-induced hepatic preneoplastic foci Carcinogenesis, September 1, 1999; 20(9): 1793 - 1799. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |